4 Interactive Tools

Tools &
Calculators

Practical resources for anyone working with research peptides, arranged so each tool feels like its own workspace instead of one long continuous form.

Dose math/Reconstitution guidance/Compound filtering/Regulatory lookup

01 Dose Calculator 02 Reconstitution Guide 03 Peptide Finder 04 Regulatory Status Tracker

Tool 01

Dose Calculator

Calculate exact injection volume from vial size and target dose. The surrounding shell stays compact so the result panel gets priority.

Vial size (mg)

Bacteriostatic water added (mL)

Desired dose

COA Purity (%)

TFA Removed

Counterion exchanged — vial weight ≈ peptide weight

Results

0.102 mL

Injection volume

10.2 IU

On 100-unit syringe

2450 mcg/mL

Concentration

19.6 doses

Per vial

Disclaimer: This calculator is for educational purposes only. These calculations do not constitute medical advice. Verify all calculations before use. Research peptides are not approved for human administration.

Tool 02

Reconstitution Guide

Interactive step-by-step protocol for reconstituting lyophilized peptides safely, with the tool contained in a clearly separated workspace.

Vial size (mg)

Target concentration (mg/mL)

5.00 mL

Water to add

500 IU

On 100-unit syringe

1 mg/mL

Final concentration

Step-by-Step Protocol

0/8 steps

🧴 Gather supplies

You need: 5 mg peptide vial, bacteriostatic water, 5.0 mL syringe (or 500 IU insulin syringe), alcohol wipes, and a clean surface.

🧼 Clean your workspace

Wash hands thoroughly. Wipe your work surface with an alcohol wipe. Allow it to air dry for 30 seconds.

💉 Prepare your syringe

Draw 5.00 mL (500 units on a 100-unit syringe) of bacteriostatic water into your syringe. Use a clean needle.

🧹 Swab the vial tops

Wipe both the bacteriostatic water vial and the peptide vial tops with fresh alcohol wipes. Allow to dry completely before puncturing.

💧 Inject water into peptide vial

Slowly inject the bacteriostatic water into the peptide vial, directing the stream toward the glass wall — not directly onto the powder. This prevents foaming and mechanical shear.

🔄 Swirl gently

Gently swirl the vial in a circular motion until fully dissolved. Do NOT shake — vigorous shaking can cause foaming and peptide degradation.

🔍 Inspect the solution

The solution should be clear to slightly cloudy. If particulates are visible after swirling, the peptide may not have fully dissolved — continue swirling or refrigerate for 10 minutes and retry.

❄️ Label and refrigerate

Label the vial with the date, peptide name, and concentration (1 mg/mL). Store at 2–8°C (refrigerator). Reconstituted peptide is stable for 28–30 days when refrigerated. Do not freeze.

Disclaimer: For educational purposes only. Research peptides are not FDA-approved for human use. Consult a physician before use.

Tool 03

Peptide Finder

Filter compounds by health goal, evidence level, and administration route to narrow the field before you dive into profiles.

01 — Select Your Goals (choose all that apply)

02 — Evidence Preference

03 — Administration Route Preference

18 Matches

Semaglutide FDA Approved

FDA approved for obesity — strongest weight loss evidence (14.9% STEP-1)

→

Tirzepatide FDA Approved

Largest weight loss in any Phase 3 trial (22.5% SURMOUNT-1)

→

Liraglutide FDA Approved

FDA approved; longest established GLP-1 safety record

→

PT-141 FDA Approved

FDA approved (Vyleesi) — only approved peptide for sexual dysfunction

→

Oxytocin Off-Label

Intranasal; social bonding, anxiety, potential sleep benefits

→

Sermorelin Off-Label

GHRH analog with human Phase I data; historically used in adult GH deficiency

→

CJC-1295 Research Only

GHRH analog; synergistic with Ipamorelin for GH release

→

Ipamorelin Research Only

Most selective GHSR agonist — minimal cortisol/prolactin spillover

→

BPC-157 Research Only

Strongest animal data for tendon/ligament repair; now 503A prohibited

→

TB-500 Research Only

RegeneRx Phase II cardiac data; actin-regulatory tissue repair mechanism

→

Thymosin Alpha-1 Research Only

Approved in 35+ countries; strongest clinical data of any research immune peptide

→

GHK-Cu Research Only

Decades of collagen and wound healing research; topical use well established

→

Semax Research Only

BDNF/NGF upregulation; Russian registration for stroke/cognitive decline

→

Selank Research Only

Anxiolytic without sedation/tolerance — GABAergic + BDNF mechanism

→

MK-677 Research Only

Oral GHSR agonist (~60–70% bioavailability) — convenience advantage

→

Epitalon Research Only

Telomerase activation claim; limited but interesting Khavinson research

→

DSIP Research Only

Direct delta wave sleep induction without GABA mechanism

→

GHRP-2 Research Only

Most potent GHSR agonist; Japan-approved for diagnostic use

→

Tool 04

Regulatory Status Tracker

Current FDA approval status, compounding availability, and sports-governance classification for major compounds.

FDA Approved

Off-Label

Research Only

503A Prohibited

Compound	FDA Status	503A Compounding	WADA	Notes
Semaglutide FDA Approved	Yes — Ozempic, Wegovy, Rybelsus	Limited — shortage ended 2025	Permitted	FDA declared shortage resolved; compounding restrictions tightening
Tirzepatide FDA Approved	Yes — Mounjaro, Zepbound	Limited — shortage period ending	Permitted	Shortage designation evolving; compounding status in flux
Liraglutide FDA Approved	Yes — Victoza, Saxenda	Limited	Permitted	Established FDA approved; less prescribed since semaglutide approval
Bremelanotide (PT-141) FDA Approved	Yes — Vyleesi (HSDD in women)	Typically not needed (brand available)	Permitted	FDA approved 2019; off-label in men
Sermorelin Off-Label	Previously — Geref withdrawn 2008	Contested — DESI exemption debated	Prohibited — GH releasing factors	Regulatory attorneys differ; verify with specific pharmacy
Oxytocin Off-Label	Yes — Pitocin (obstetric use)	Permitted with Rx — under review	Permitted	Approved drug used off-label; intranasal compounding under FDA scrutiny
BPC-157 503A Prohibited	No	❌ Prohibited — November 2023	Prohibited — S0 experimental	FDA final rule prohibits 503A compounding; research chemical status intact
CJC-1295 503A Prohibited	No	❌ Prohibited — November 2023	Prohibited — GHRH	Both DAC and no-DAC versions prohibited from 503A
Ipamorelin 503A Prohibited	No	❌ Prohibited — November 2023	Prohibited — GH secretagogues	Often combined with CJC-1295; both now prohibited
TB-500 (Thymosin β-4) 503A Prohibited	No	❌ Prohibited — November 2023	Prohibited — S2 peptide hormones	RegeneRx Phase II but not approved; 503A prohibited
Thymosin Alpha-1 503A Prohibited	No (approved outside US)	❌ Prohibited — November 2023	Prohibited — S4 hormone/metabolic	Approved in 35+ countries; Zadaxin not available in US commercially
Selank Research Only	No	Not typically available	Permitted	Russian registration; research chemical in US
Semax Research Only	No	Not typically available	Permitted	Russian registration for stroke/TBI; research chemical in US
GHK-Cu Research Only	No (cosmetic use)	Topical may be available	Permitted (topical)	Primarily topical cosmetic use; systemic research-only
MK-677 (Ibutamoren) Research Only	No (IND withdrawn)	Not a peptide; not compoundable	Prohibited — GH secretagogues	Non-peptide GHSR agonist; oral; research chemical status

Last reviewed: August 2025. Regulatory status changes frequently. Verify current status with a licensed pharmacist or attorney. Full regulatory guide →

Tools &Calculators

Dose Calculator

Reconstitution Guide

Peptide Finder

Regulatory Status Tracker

Tools &
Calculators